Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Agility cannot assess the financial impact at the moment.
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Makhazen Names Ahmad Al-Banna CEO, Khaled Al-Ghais Vice Chairman
Learn More
Download Report
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Commenting on published news
Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Agility cannot assess the financial impact at the moment.
Sincerely,
Investor Relations Team
Latest Financial News
April 27, 2026
Supplementary Disclosure Related to Legal Cases
April 23, 2026
Disclosure Related to Legal Cases
April 23, 2026
Disclosure Related to Legal Cases – Update
April 21, 2026
Makhazen’s Annual General Assembly Meeting
April 9, 2026
Clarification on the news
March 29, 2026
Results of the Analysts Call for FY 2025